Biotech News
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1%
